Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jmii.2020.09.002 http://scihub22266oqcxt.onion/10.1016/j.jmii.2020.09.002 33060041!7534785!33060041     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Microbiol+Immunol+Infect 2021 ; 54 (1): 27-36 Nephropedia Template TP {{tp|p=33060041|t=2021. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review |pdf=|usr=}}{{33060041}} gab.com Text Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review JO: J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33060041 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Twit Text FOAVip Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review ????J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33060041 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33060041 #FOAvip English Wikipedia <ref>{{Cite pmid|33060041}}</ref> Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review #MMPMID33060041 Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR J Microbiol Immunol Infect 2021[Feb]; 54 (1): 27-36 PMID33060041show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/administration & dosage/*analogs & derivatives[MESH] |Alanine/administration & dosage/*analogs & derivatives[MESH] |Antiviral Agents/*administration & dosage[MESH] |COVID-19/epidemiology[MESH] |China/epidemiology[MESH] |Clinical Trials as Topic[MESH] |Humans[MESH] |Pandemics[MESH] |Randomized Controlled Trials as Topic[MESH]Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review(epmc).pdf DeepDyve Pubget Overpricing